Educating Patients on Treatment Options in Metastatic HSPC

EP: 1.Breakthroughs in Imaging Modalities for Prostate Cancer

EP: 2.Prostate Cancer Imaging: Unmet Needs and Knowledge Gaps

EP: 3.Recent Progress in the Prostate Cancer Treatment Landscape

EP: 4.Key Unmet Needs in Prostate Cancer Management

EP: 5.Goals of Treatment for Non-metastatic Castration-Resistant Prostate Cancer

EP: 6.nmCRPC: Clinical Trial Data on AR Inhibitors

EP: 7.AR Inhibitors in nmCRPC: Real-World Data

EP: 8.Importance of Quality of Life When Choosing Therapy for nmCRPC

EP: 9.Non-metastatic Castration-Resistant Prostate Cancer: Patient Monitoring Strategies

EP: 10.Optimizing Care for Patients With Non-metastatic CRPC

EP: 11.Treatment Goals for Patients With Metastatic Hormone-Sensitive Prostate Cancer

EP: 12.Factors in Selecting Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

EP: 13.mHSPC: Use of Triplet Therapy

EP: 14.Metastatic Hormone-Sensitive Prostate Cancer: Data From ARASENS and ARANOTE

EP: 15.Metastatic Hormone-Sensitive Prostate Cancer: Data From ENZAMET and ARCHES

EP: 16.Metastatic Hormone-Sensitive Prostate Cancer: Data from TITAN and PEACE-1

Now Viewing

EP: 17.Educating Patients on Treatment Options in Metastatic HSPC

EP: 18.Novel Treatment Modalities in Metastatic Hormone-Sensitive Prostate Cancer

EP: 19.Overview of the Metastatic Castration-Resistant Prostate Cancer Treatment Paradigm

EP: 20.Metastatic CRPC: Advent of PARP Inhibitors

EP: 21.Practical Application of PARP Inhibitors in Metastatic CRPC

EP: 22.IO Therapy in mCRPC and Clinical Pearls

Transcript:

Alan Bryce, MD: We have this embarrassment of riches, and it’s a wonderful problem to have, trying to figure out who gets which regimen, and recognizing how quickly the field is moving forward. To anybody on the panel, what will you tell your patients about why you’re selecting doublet versus triplet [therapy]? Or, and I think we’ll talk about that next, let’s start talking about clinical trials and the other combinations. We’re not slowing down in this first-line setting. Say the patient comes in after having read online, they’ve got a lot of advice coming to them from different directions, what does the decision-making hinge on? We talked about fitness and risk, and how we describe risk is probably where we have the biggest uncertainty. Volume is easy, or metastasis—liver metastases are easy. But how do we talk to the patient about risk?

Edwin Posadas, MD: There are things the patients already hear: the Gleason score, certain patterns of metastasis, we can explain they’re bad. Everyone is familiar with bone metastases and lymph node, liver, lung, those always send a red flare up saying you’re starting in a tougher position. Those always make you want to be a little more aggressive, and when a patient hears that they’re falling out of the norm, they’re a little more inclined to take that lead, especially when you can back it up with some literature. Looking at the ARASENS study as an example, but even in LATITUDE, when you start seeing these higher-risk features, you need to be more rather than less aggressive. But then you’ve got to balance that same discussion with who’s chemotherapy fit and who’s intensified AR [androgen receptor] suppression fit. That has already come up here, where we’re balancing overall survival with quality of life and other comorbid conditions. This is why medicine is still an art and not a cookbook type of profession.

Transcript edited for clarity.